Edwards Lifesciences is betting on a big opportunity in transcatheter mitral valve replacement, but offers up very few details on the status of its efforts in that area. Edwards Lifesciences continued to wow analysts with its transcatheter heart valve sales results on its earnings call on Monday, but to a certain extent the attention of analysts has shifted to what they hope will be the next thing pushing revenue higher: Transcatheter mitral valve replacement.